Blood tests Fine-Tune leukemia drug combo to cut infection risk
NCT ID NCT07254611
First seen Dec 18, 2025 · Last updated May 24, 2026 · Updated 19 times
Summary
This study looked at 15 older adults with acute myeloid leukemia (AML) who were getting a standard drug combo (azacitidine or decitabine plus venetoclax). Because these drugs can lower infection-fighting white blood cells, patients often take an antifungal called posaconazole. The problem is posaconazole can raise venetoclax levels too high, causing more side effects. Researchers measured venetoclax in the blood to see how many patients reached a stable, safe level by day 12, aiming to guide proper dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.